Dudediligence.

Humacyte, Inc

HUMANASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Price
FilingsNewest: 8-K, Director or officer changeSep 28 →Insiders2 insiders bought $59,790 in 2 open-market buys. 2 insiders sold $82,597, all 2 sales on a 10b5-1 plan.→HoldersAntipodes Partners 3.6%Vanguard 3.6%Alyeska Investment 2.2%→Financing →PeersClosest companies: OBIO, TNYA, CABA→

From the filings

Figures

Revenue
$2.1Mlast 12 months
Net income
−$96.7Mlast 12 months
Operating cash flow
−$101.5Mlast 12 months
Cash and equivalents
$79.9Mat the last balance sheet
Total debt
$36.3Mat the last balance sheet
Shares outstanding
277.8M shareson issue
Every year and quarter →